EcoDrugPlus

Met Proto-Oncogene, Receptor Tyrosine Kinase

Ensembl ID : ENSSDUG00000016591
Gene Symbol: MET
3 Cross references
205 Possible Orthologues:

Mtor Associated Protein, Lst8 Homolog

Ensembl ID : ENSSDUG00000005876
Gene Symbol: MLST8
2 Cross references
172 Possible Orthologues:

Mtor Associated Protein, Lst8 Homolog (S. Cerevisiae)

Ensembl ID : ENSSDUG00000005898
Gene Symbol: MLST8
1 Cross references
192 Possible Orthologues:

Nad(P)h Dehydrogenase [Quinone] 1-Like

Ensembl ID : ENSSDUG00000004023
Gene Symbol: LOC111218686
4 Cross references
186 Possible Orthologues:

Npc1 Like Intracellular Cholesterol Transporter 1

Ensembl ID : ENSSDUG00000021900
Gene Symbol: NPC1L1
4 Cross references
189 Possible Orthologues:

P2x Purinoceptor 3-Like

Ensembl ID : ENSSDUG00000006439
Gene Symbol: LOC111230481
3 Cross references
195 Possible Orthologues:

P2x Purinoceptor 3-Like

Ensembl ID : ENSSDUG00000014746
Gene Symbol: LOC111232413
3 Cross references
192 Possible Orthologues:

P2y Purinoceptor 12-Like

Ensembl ID : ENSSDUG00000014404
Gene Symbol: LOC111239159
3 Cross references
180 Possible Orthologues:

Pim-3 Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSSDUG00000011485
Gene Symbol: PIM3
3 Cross references
172 Possible Orthologues:

Rac-Beta Serine/threonine-Protein Kinase

Ensembl ID : ENSSDUG00000012450
Gene Symbol: LOC111233400
3 Cross references
210 Possible Orthologues:

Rac-Beta Serine/threonine-Protein Kinase-Like

Ensembl ID : ENSSDUG00000015655
Gene Symbol: LOC111234315
3 Cross references
161 Possible Orthologues:

Rac-Gamma Serine/threonine-Protein Kinase

Ensembl ID : ENSSDUG00000018670
Gene Symbol: LOC111235389
3 Cross references
203 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).